Johnson & Johnson Snags Animas To Advance Artificial Pancreas Design
This article was originally published in The Gray Sheet
Executive Summary
Johnson & Johnson/LifeScan will acquire long-sought access to the continuous glucose monitoring system (CGMS) market with its $518 mil. purchase of Animas, the firm announced Dec. 16
You may also be interested in...
J&J Device Sales Growth Led By Diabetes, Vision Care As Q4 Stent Sales Sink
Johnson & Johnson's diabetes and vision care businesses generated the highest growth levels across the firm's device sector in the fourth quarter with each achieving operational growth of 12% compared to a year ago, the firm reported Jan. 23
J&J Device Sales Growth Led By Diabetes, Vision Care As Q4 Stent Sales Sink
Johnson & Johnson's diabetes and vision care businesses generated the highest growth levels across the firm's device sector in the fourth quarter with each achieving operational growth of 12% compared to a year ago, the firm reported Jan. 23
J&J To Focus On Small-To-Medium Size Acquisitions For The Time Being
J&J is targeting more small-to-medium size companies for acquisition now that ICD-maker Guidant is out of reach